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Abstract  
We examined the effects of osteocyte secreted factors on myogenesis and muscle function. MLO-
Y4 osteocyte-like cell conditioned media (CM) (10%) increased ex vivo soleus muscle contractile 
force by ~25%.  MLO-Y4 and primary osteocyte CM (1-10%) stimulated myogenic differentiation 
of C2C12 myoblasts, but 10% osteoblast CMs did not enhance C2C12 cell differentiation. Since 
WNT3a and WNT1 are secreted by osteocytes, and the expression level of Wnt3a is increased in 
MLO-Y4 cells by fluid flow shear stress, both were compared, showing WNT3a more potent than 
WNT1 in inducing myogenesis. Treatment of C2C12 myoblasts with WNT3a at concentrations as 
low as 0.5ng/mL mirrored the effects of both primary osteocyte and MLO-Y4 CM by inducing 
nuclear translocation of β-catenin with myogenic differentiation, suggesting that Wnts might be 
potential factors secreted by osteocytes that signal to muscle cells.  Knocking down Wnt3a in 
MLO-Y4 osteocytes inhibited the effect of CM on C2C12 myogenic differentiation. Sclerostin 
(100ng/mL) inhibited both the effects of MLO-Y4 CM and WNT3a on C2C12 cell differentiation. 
RT-PCR array results supported the activation of the Wnt/β-catenin pathway by MLO-Y4 CM and 
WNT3a. These results were confirmed by qPCR showing up-regulation of myogenic markers and   
two Wnt/β-catenin downstream genes, Numb and Flh1. We postulated that MLO-Y4 CM/WNT3a 
could modulate intracellular calcium homeostasis as the trigger mechanism for the enhanced 
myogenesis and contractile force. MLO-Y4 CM and WNT3a increased caffeine-induced Ca2+ 
release from the sarcoplasmic reticulum (SR) of C2C12 myotubes and the expression of genes 
directly associated with intracellular Ca2+ signaling and homeostasis. Together, these data show 
that in vitro and ex vivo, osteocytes can stimulate myogenesis and enhance muscle contractile 
function and suggest that Wnts could be mediators of bone to muscle signaling, likely via 
modulation of intracellular Ca2+ signaling and the Wnt/ β-Catenin pathway. This article is protected 
by copyright. All rights reserved 
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Introduction 
   Muscle and bone are connected both anatomically and functionally and interact as a 
functional unit (1). Musculoskeletal diseases are the most common cause of chronic disabilities 
worldwide. Osteoporosis/osteopenia (loss of bone tissue and function) and sarcopenia 
(progressive muscle loss with a greater and disproportional loss of muscle force/strength) are 
inevitable consequences of the aging process and prevalent in the frail elderly and have become a 
growing public health concern (2).  
The emerging field of bone-muscle crosstalk is helping to clarify the role of bones and 
muscles as endocrine organs because they produce and secrete “hormone-like factors” that can 
mutually influence each other and other tissues (3, 4).  Recently, evidence has emerged that 
osteocytes secrete factors that have profound effects on C2C12 muscle cells in culture, and vice 
versa (3, 5), suggesting that muscle and bone communicate at a molecular level via biochemical 
factors that are reciprocally important for optimal function (6).   
Bones secrete a host of factors that have clear paracrine and endocrine effects, such as 
FGF23, Sclerostin, Osteocalcin, WNTs, Prostaglandin E2 (PGE2), etc. (reviewed in (7)). 
Sclerostin is one of these factors, which has gained much attention because of recent clinical 
applications and trials (8). Sclerostin is one of the osteocyte-specific proteins, and is product of 
the SOST gene (9), which is expressed by mature osteocytes (10, 11). Sclerostin is a negative 
regulator of Wnt/β-catenin signaling pathway by binding to the Wnt coreceptors, low-density 
lipoprotein receptor-related proteins 5 and 6 (LRP5 and LRP6) (12). In the presence of Sclerostin, 
Wnt-receptor interaction is inhibited, and β-catenin is phosphorylated by glycogen synthase 
kinase 3 and targeted for ubiquitination and degradation via the proteosome pathway (13). Studies 
using loss of function and gain of function mouse models of Sost have demonstrated increased 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
and decreased bone mass, respectively (10). Our earlier studies demonstrated that many of the 
effects of bone cell conditioned medium in triggering acceleration of myogenesis could be 
partially mimicked by low nanomolar range concentrations of PGE2 (3).  
The Wnt /β-catenin signaling pathway is important for cell and tissue homeostasis, since 
secreted WNTs act through specific receptors to control and modulate cell proliferation, 
differentiation, apoptosis, survival, migration, and polarity (reviewed in (14)). They play critical 
roles during embryonic development (including muscle and skeletal patterning) as well as in 
postnatal health and diseases, including cancer and degenerative disorders. The Wnt/β-catenin 
signal pathway has been shown to be an important component of bone mass accrual, regulation 
and maintenance (15), and accumulating data show that the Wnt/β-catenin signal pathway is 
strongly implicated in the skeletal muscle development, growth and regeneration (16).    
To determine whether osteocytes can potentially regulate muscle function, we tested the 
effects of MLO-Y4 conditioned medium (MLO-Y4 CM) on muscle contractility in soleus (SOL) 
muscles using a murine ex vivo muscle contractility assay and found out that MLO-Y4 CM 
increased the contractile force of SOL muscles. To gain new insight into the mechanisms of bone 
to muscle signaling we have used MLO-Y4 osteocyte-like cells, osteoblast cells, primary 
osteocytes and C2C12 myoblasts as in vitro models. We report that MLO-Y4 cells and primary 
osteocytes secrete factors that potently stimulate myogenesis, accompanied by enhanced β-
catenin translocation, suggesting that the effect may be mediated via Wnt/β-catenin signaling.  
However, 10% osteoblast CMs did not enhance C2C12 cell differentiation. We therefore 
investigated the expression of Wnts in osteocytes and showed that WNT3a, which is expressed 
in osteocytes, mirrored the effects of osteocyte conditioned medium on myogenesis. Knocking 
down Wnt3a in MLO-Y4 osteocytes inhibited the effect of CM on C2C12 myogenic 
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differentiation. Sclerostin inhibited the effects of CM or WNT3a on C2C12 cell differentiation. 
To determine potential mechanisms of contractile force enhancement, we examined the effects of 
osteocyte conditioned medium on calcium release from the sarcoplasmic reticulum (SR). Our in 
vitro and ex vivo data show that osteocytes secrete soluble factors that enhance myogenic 
differentiation, enhance both contractile force and calcium release from the SR, and provide 
evidence that WNT3a is a potential factor from osteocytes with the intrinsic potential to 
modulate these effects of bone-muscle crosstalk.  
Materials and methods 
Materials 
DMEM high glucose media, αMEM media, penicillin-streptomycin (P/S) 10,000 U/mL each and 
trypsin-EDTA 1× solution were obtained from Mediatech Inc. (Manassas, VA, USA); calf serum 
(CS), fetal bovine serum (FBS), horse serum (HS) and caffeine were obtained from Thermo 
Fischer Scientific Inc. (Waltham, MA, USA); bovine serum albumin (BSA), diamidino-2-
phenylindole (DAPI) were from Sigma-Aldrich (St Louis, MO, USA); rat tail collagen type I  
was purchased from BD Biosciences (San Jose, CA, USA); 16% paraformaldehyde was from 
Alfa Aesar (Ward Hill, MA, USA); Recombinant Mouse Wnt-3a and Recombinant Mouse 
SOST/Sclerostin protein was purchased from R&D Systems Inc. (Minneapolis, MN, USA); 
WNT1 Recombinant Human Protein was obtained from Life Technologies. (Grand Island, NY, 
USA); Cy-3 donkey anti-mouse were purchased from Invitrogen. (Carlsbad, CA, USA); This 
antibody has been previously validated (5). Mouse anti-active β-catenin antibody was from 
Millipore. (Billerica, MA, USA); This antibody has been previously validated (5).  
Lipofectamine® RNAiMAX Transfection Reagent was from ThermoFisher Scientific. 
(Waltham, MA, USA); Wnt3a siRNA (antisense strand: 5’-
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GCAUCCGCUCUGACACUUAAUACTC-3’), negative control siRNA and TYE 563 DS 
Transfection Control was from Integrated DNA Technologies. (Coralville, Iowa, USA); Tri 
reagent was obtained from Molecular Research Center, Inc. (Cincinnati, OH, USA); High 
capacity cDNA reverse transcription kit was from Applied Biosystems. (Foster city, CA, USA); 
RT2 Real-TimeTM SYBR green/Rox PCR master mix was from SABiosciences. (Valencia, CA, 
USA); Anti-human Myosin Heavy Chain-CFS, Carboxyfluorescein (CFS)-conjugated mouse 
monoclonal anti-human Myosin Heavy Chain antibody was from R&D Systems Inc. 
(Minneapolis, MN, USA); This antibody has been previously validated (6).  Fura-2/AM was 
obtained from Life Technologies (Grand Island, NY, USA). C2C12 cells were obtained from 
American Type Culture Collection (ATCC) (Manassas, VA, USA). Gentamycin and 2-APB; 
Wingless Type MMTV Integration Site Family, Member 3A (WNT3A) ELISA Kit was 
purchased from MyBioSource. (San Diego, CA, USA). 
Methods 
No in vivo experiments were conducted in this study. 
Animals 
Five month old male C57BL/6 mice from Jackson Laboratory were used for isolation of bone 
cells and isolation of intact muscles for ex vivo contractility studies, following humane 
euthanasia cervical dislocation.  All animal procedures were performed according to an approved 
IACUC protocol at the University of Missouri-Kansas City (UMKC), and conformed to relevant 
federal guidelines. The UMKC animal facility is operated as a specific pathogen-free, AAALAC 
approved facility.  Animal care and husbandry at UMKC meet the requirements in the Guide for 
the Care and use of Laboratory Animals (8th edition), National Research Council. Animals were 
group housed and maintained on a 12-hour light/dark cycle with ad libitum food and water at a 
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constant temperature of 72oF and humidity of 45-55%. Daily health check inspections were 
performed by qualified veterinary staff and/or animal care technicians. 
Ex vivo muscle contractility 
Dissection and setup: Mice were humanely sacrificed and soleus muscles were carefully 
removed for contractility analysis, as previously reported (17) and following the Protocol of the 
Treat-NMD Network (DMD_M.1.2.002).  Dissected soleus muscles were immediately placed in 
a dish containing a HEPES Ringer solution (143 mM NaCl; 5 mM KCl; 1.8 mM MgCl2; 10 mM 
HEPES; 2.5 mM CaCl2; pH 7.40) with 10 mM glucose. This solution was continuously aerated 
with 100% O2. Muscles were mounted vertically between two stimulating platinum electrodes 
and immersed in a 25 mL bathing chamber containing the Ringer solution. Via the tendons, the 
muscles were suspended from adjustable isometric force transducers above the chambers and 
secured to the base of the tissue support within the chambers. The analog output of the force 
transducer was digitized, stored and analyzed with PowerLab® Software (ADInstruments Inc., 
Colorado Springs, CO, USA). For each muscle the stimulatory voltage was provided by an 
S8800 dual pulse digital stimulator (Grass Products, West Warwick, RI, USA) (pulse duration, 1 
ms; train duration, 500 ms). Optimal muscle length (L0) was determined by tetanic stimulations 
of 100 Hz at an interval of 1 minute.  Equilibration: The intact muscles were allowed a 30 
minutes equilibration period during which time they were stimulated with pairs of alternating 
high (100 Hz) and low (20 Hz) frequency pulse-trains administered with a periodicity of 1 
minute.  Utilization of the proposed paradigm of stimulation helps with the study of the relative 
contributions of the contractile proteins (100 Hz) and the SR (20 Hz) to contractile function (17). 
After equilibration and stabilization of submaximal and maximal forces, blank medium or MLO-
Y4 CM was added to the control and test muscle, respectively and force was followed for 30 
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minutes after the addition of the media. Force normalization: Muscle force was reported as 
relative force (mN) and force normalized to muscle physiological cross sectional area (N/cm2) as 
previously reported by our group (17-19). Five animals and 10 muscles were used for final 
analyses.  
Cell cultures and generation of conditioned medium (CM) from primary osteocytes (PO 
CM), MLO-Y4 cells (MLO-Y4 CM), 2T3 cells (2T3 CM) and MC3T3-E1 (MC3T3-E1 CM) 
Cell culture: C2C12 myoblasts were cultured following our own previously published protocols 
(3, 5, 6). Briefly, cells were grown at 37°C in a controlled humidified 5% CO2 atmosphere in 
growth medium (GM), DMEM/high glucose +10% FBS (100U/mL P/S), and maintained at 40 -
70% cell density. Under these conditions, myoblasts proliferate, but do not differentiate into 
myotubes. During myoblast proliferation, medium was changed every 48 hours. To induce 
differentiation of myoblasts into myotubes, when cells reached 75% confluence, the culture 
media were switched from GM to differentiation medium (DM), DMEM/high glucose + 2.5% 
horse serum (HS) (100U/mL P/S), and DM was changed every 48 hours. Fully differentiated, 
functional, contracting myotubes were formed within 5-7days.  
MLO-Y4, a murine long bone-derived osteocyte-like cell line (referred to hereafter as MLO-Y4 
cells), were cultured as previously described (20). Briefly, cells were seeded onto type I collagen-
coated plates and cultured in αMEM + 2.5% FBS + 2.5% CS (100U/mL P/S). Cells were 
maintained at ~60% confluence throughout the culture period.  
2T3 osteoblast-like cells (referred to hereafter as 2T3 cells) were cultured as previously 
described (21) with a few modifications.  Briefly, cells were cultured in αMEM + 10% FBS 
(100U/mL P/S). Cells were maintained at ~60% confluence throughout the culture period.  
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MC3T3-E1 preosteoblast cells (referred to hereafter as MC3T3-E1 cells) were cultured as 
previously described (22). Briefly, cells were cultured in αMEM + 10% FBS (100U/mL P/S). 
Cells were maintained at ~60% confluence throughout the culture period.  
Generation of CMs from primary osteocytes (PO CM), MLO-Y4 cells (MLO-Y4 CM), 2T3 cells 
(2T3 CM) and MC3T3-E1 cells (MC3T3-E1 CM): The method of isolation of primary osteocytes 
was described by Stern et al.(23, 24), with minor modifications. Briefly, long bones were dissected 
and muscles were removed taking care not to remove the periosteum. Epiphyses were cut and 
bone marrow was then flushed out.  The bones were cut into small pieces (1-2 mm2) and 
incubated for 25 minutes in collagenase solution (300 units/mL) with constant shaking in an 
incubator at 37ºC and 5% CO2.  Solution was then removed and centrifuged.  Cells were then re-
suspended in 10% FBS containing αMEM and plated in collagen-coated plates (fraction 1- 
fibroblast-enriched).  Bone chips were then subsequently incubated with fresh collagenase 
solution to obtain fractions 2 to 4 (osteoblast-enriched).  Then bone chips were digested in 
alternating EDTA (5 mM) and collagenase solutions to obtain fractions 5 to 9 (osteocyte-
enriched). The remaining bone pieces were transferred into collagen-coated dishes and cells 
migrated from the bone pieces after 3–5 days of culture (fraction 10-bone particles). All of the 
cells obtained from fractions 5 to 9 that displayed an osteocyte-like morphology stained positive 
for the osteocyte marker E11/GP38. The osteocyte phenotype was further confirmed by a lack of 
staining for alkaline phosphatase and the absence of collagen1a1 expression. The osteocytes also 
expressed additional osteocyte-specific genes such as Sost and Mepe. To generate PO CM, cells 
of fractions 5 to 9 were cultured in 60 cm2 collagen-coated plates with αMEM + 5 % FBS + 5 % 
CS (1,000 U/mL P/S) culture media, 3600 cells/cm2 and allowed to attach and grow for 48 hours. 
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The medium was collected and centrifuged at 500 × g for 10 minutes. Conditioned medium 
(CM) was aliquoted and flash frozen in liquid nitrogen then stored at -80°C.  
To prepare MLO-Y4 CM, 2T3 CM and MC3T3-E1 CM, MLO-Y4, 2T3 and MC3T3-E1 cells 
were plated in 10cm dishes, 5000 cells/cm2 and allowed to attach and grow for 48 hours. The 
medium was collected and centrifuged at 500 × g for 10 minutes. Conditioned medium (CM) 
was aliquoted and flash frozen in liquid nitrogen then stored at -80°C. 
Fluid flow shear stress (FFSS) treatment of MLO-Y4 and 2T3 cells  
At day 1, MLO-Y4 and 2T3 cells were seeded onto glass slides coated with type I collagen at a 
density of 5,600 cells/cm2 in alpha-MEM supplemented with either 2.5% calf serum (CS), 2.5% 
fetal bovine serum (FBS) and 1% P/S (for MLO-Y4 cells) or 10% FBS and 1% P/S (for 2T3 
cells) for 24 hours.  At day 2, shear stress was applied to the slides at 2 dynes/cm2 for 2 hours in 
alpha-MEM supplemented with 0.1% CS, 0.1% FBS and 1% P/S.  For fluid flow shear stress, 
350 mL media was used to run the system (6 slides per run). For static controls, three slides were 
placed in a 150 mm round tissue culture dish with 175 mL of alpha-MEM media (1% P/S) 
containing 0.1% CS and 0.1% FBS. Media was collected after 2 hours of shear stress. Three 
slides of seeded cells were used for RNA isolation at the end of the 2 hours of shear stress (or 
static culture). The other 3 slides were incubated in regular media (alpha-MEM supplemented 
with 2.5% CS, 2.5% FBS and 1% P/S) for 24 hours. RNA was extracted from both static and 
shear stressed slides, 2 hours and 24 hours after FFSS for RT-qPCR detection of gene 
expression. 
ELISA for WNT3a in PO CM and MLO-Y4 CM 
WNT3a in PO CM and MLO-Y4 CM was detected by Wingless Type MMTV Integration Site 
Family, Member 3A (WNT3A) ELISA Kit according to the manufacturer's protocol. Serum-free 
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CM were collected from the cells that were cultured for twenty four hours, and 100 μl CM was 
added into the ELISA plate wells coated with a biotin-conjugated WNT3a antibody. Next, 
Avidin conjugated to Horseradish peroxidase is added and incubated for 1 hour. After TMB 
substrate solution is added, the color change is measured spectrophotometrically at 450 nm. The 
concentration of WNT3a is then determined by comparing the O.D. of the samples to the 
standard curve. Three independent experiments with 2 replicates were performed for these 
experiments. 
Immunolabeling of active β-catenin for nuclear translocation 
These studies followed our previous protocols (25) with minor modifications for C2C12 cells.  
Briefly, C2C12 cells were seeded onto positively-charged glass slides and cultured overnight. 
CMs or blank media was added to produce 10% final concentration. Cells were incubated for 30 
minutes, 60 minutes and 90 minutes respectively, rinsed two times in cold PBS, fixed in 2% 
paraformaldehyde containing 0.2% Triton X-100 for 10 minutes and then washed three times in 
PBS at ambient temperature for 10 minutes each. Slides were blocked with 2.5 % BSA and 1% 
normal donkey serum in PBS overnight at 4 °C. Primary antibody against the active form of β-
catenin was used at 1:100 dilution in blocking buffer for 4 hours at ambient temperature. Slides 
were washed three times with PBS and incubated for 1 hour with Cy3 -conjugated donkey anti-
mouse antibody. The quantification of the intensity of β–catenin immunofluorescence was 
performed as described previously using a Leica TCS SP5 II confocal microscopy system on an 
inverted microscope platform (26).  16 bit images were obtained and were pseudo colored in green 
and analyzed using ImageJ Software (NIH). The nuclear and cytoplasmic histograms from each 
image were used to quantify staining intensity. Three independent experiments with 5-10 cells 
monitored on each individual experiments.  
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C2C12 Cell Morphometry and Immunostaining  
Cell Morphology: Phase contrast images were taken with a LEICA DMI-4000B inverted 
microscope equipped with a 14-BIT CoolSNAP CCD camera (Photometrics), using the LEICA 
LAS imaging software for calibration (Leica microsystems).  
Immunostaining:  Experiments were performed following our published protocols (5, 6, 27). 
Briefly, C2C12 cells were fixed with neutral buffered formalin and permeabilized with 0.1% 
Triton X-100. Myosin heavy chain (MHC) was detected with Anti-Human Myosin Heavy Chain-
CFS (1:50) at room temperature for 30 minutes and counter stained with DAPI. Images were 
taken using a 20X LEICA FLUO objective with the LEICA system described above. Fusion 
index: To quantify myogenic differentiation of C2C12 cells after treatments, the Fusion Index 
(FI) was calculated, where FI is defined as: (nuclei within myosin heavy chain-expressing 
myotubes/total number of myogenic nuclei) × 100 (28).  We conducted 3-5 independent 
experiments, 2 replicates, and 3-5 areas per replicate were randomly selected for the 
measurements.  
Treatment of C2C12 cells with PO CM, MLO-Y4 CM, 2T3 CM, MC3T3-E1 CM and 
WNT3a 
C2C12 cells were plated in 6-well plates, 10×104/well, and allowed to attach and grow overnight. 
Medium of C2C12 myoblasts were changed from GM to DM with CMs and WNT3a, 
respectively, 48 hours later, changed medium with fresh DM.  CMs and WNT3a were removed 
from the medium. At day 3 of differentiation, C2C12 cells were analyzed according to “C2C12 
Cell Morphometry and Immunostaining” described above. 
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Treatment of MLO-Y4 cells with Wnt3a siRNA and generation of CM from Wnt3a siRNA 
treated MLO-Y4 cells (MLO-Y4 siRNA-treated CM) 
MLO-Y4 cells were plated in 6-well plates, 5×104 cells/well, and allowed to attach and grow 
overnight.  Cells were transfected with Lipofectamine® RNAiMAX Transfection Reagent 
following the manufacturer's instructions.  First, TYE 563 DS Transfection Control which is 
tagged with a red fluorescent probe was used to detect the transfection efficiency. To knock 
down Wnt3a, MLO-Y4 cells were treated with 10 nM Wnt3a siRNA+ 9 µl Lipofectamine® 
RNAiMAX reagent (MLO-Y4-siRNA-treated cells), while negative control cells were treated 
with 10 nM negative control siRNA + 9 µl Lipofectamine® RNAiMAX reagent. We further 
employed a vehicle control by treating the cells with only 9 ul Lipofectamine® RNAiMAX 
reagent without siRNA.  After 24 hours of transfection, total RNA was isolated from the cells 
with Tri reagent and Wnt3a expression was detected by RT-qPCR.  To prepare the conditioned 
medium (CM) of MLO-Y4 cells transfected with Wnt3a siRNA, 24 hours after siRNA 
transfection, medium was changed with fresh medium and the cells were cultured for 48 hours, 
then CM was collected and centrifuged at 500 × g for 10 minutes. CM was aliquoted and flash 
frozen in liquid nitrogen then stored at -80°C.  The CMs of negative control and Lipofectamine® 
RNAiMAX reagent-only vehicle treated cells (vehicle control) were also collected. Three 
independent experiments were performed.  
Treatment of C2C12 cells with MLO-Y4 siRNA-treated CM 
C2C12 cells were plated in 6-well plates, 10×104/well, and allowed to attach and grow overnight. 
Medium of C2C12 myoblasts were changed from GM to DM with 10% CMs, respectively, 48 
hours later, changed medium with fresh DM. CMs were removed from the medium. At day 3 of 
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differentiation, C2C12 cells were analyzed according to “C2C12 Cell Morphometry and 
Immunostaining” described above.  
 
Treatment of C2C12 cells with Sclerostin  
C2C12 cells were plated in 6-well plates, 10×104/well, and allowed to attach and grow overnight. 
a) C2C12 myoblasts in DM without Sclerostin treatment as a negative control. b) C2C12 
myoblasts were treated with 100ng/mL Sclerostin in DM for 6 hours. c) C2C12 myoblasts were 
treated in DM with 10% MLO-Y4 CM for 48 hours as one of our positive controls. d) C2C12 
myoblasts were treated in DM with 10ng/mL WNT3a for 48 hours as our second positive 
control. e) C2C12 myoblasts were treated with 100ng/mL Sclerostin in DM for 6 hours, followed 
by 10% MLO-Y4 CM for 48 hours; f) C2C12 myoblasts were treated with 100ng/mL Sclerostin 
in DM for 6 hours, followed by 10ng/mLWNT3a for 48 hours; g) C2C12 myoblasts were treated 
with 100ng/mL Sclerostin in DM for 6 hours, followed by the combination of 10% MLO-Y4 CM 
+ 10ng/mLWNT3a for 48 hours. Under any experimental where Sclerostin, CM, WNT3a was 
used, they were maintained during treatments for 48 hours.  After 48 hours, medium was 
changed with fresh DM. Sclerostin, CM, and WNT3a were removed from the media. At day 3 of 
differentiation, C2C12 cells were analyzed according to “C2C12 Cell Morphometry and 
Immunostaining” described above.  
RNA isolation and real time quantitative PCR (RT-qPCR) 
Total RNA was isolated from the cells with Tri reagent according to the manufacturer's protocol 
and cDNA was synthesized using a high capacity cDNA reverse transcription kit.  RT-qPCR was 
performed using RT2 Real-TimeTM SYBR green/Rox PCR master mix. RT-qPCR primers used in 
this study are summarized in Table 1. RT-qPCR was run in a 25μl reaction volume on 96-well 
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plates using a StepOnePlus instrument (Applied Biosystems, Foster city, CA, USA). Data were 
analyzed using RT² Profiler™ PCR Array Data Analysis (SABiosciences); Ct values were 
normalized to Gadph (Glyceraldehyde-3-phosphate dehydrogenase) as a reference gene. Gene 
expression was determined as fold up or down regulation of the gene of interest compared to the 
controls. All reactions were done in duplicate and all experiments were repeated at least three 
times. 
RT-PCR Gene Arrays  
The Mouse Signal Transduction PathwayFinder PCR Array from SABiosciences was used to 
simultaneously detect gene expression changes of 10 signaling pathways (see details in Table 2). 
cDNA was synthesized using the RT² First Strand Kit (This kit contains genomic DNA 
elimination process) and the PCR Array was run according to the manufacturer's protocol 
including a threshold of 0.25 and validation of each gene tested by the identification of single 
peaks in melting curves. As above, data were analyzed using the RT² Profiler™ PCR Array Data 
Analysis Software; Ct values were normalized to six built-in reference housekeeping genes, 
genomic DNA control, reverse transcription control, and positive PCR control. We used this 
analytical software (http://www.qiagen.com/us/shop/genes-and-pathways/data-analysis-center-
overview-page/) to set the statistical significance of up/down regulation of all tested genes at 2-
fold difference. Three independent experiments were performed. 
Intracellular Ca2+ measurements 
A Photon Technology International (PTI) imaging system was used to measure intracellular 
calcium transients. The intracellular calcium transients produced by the stimulation of calcium 
release from sarcoplasmic reticulum (SR) with 20 mM caffeine were measured.  Each myotube 
imaged was loaded with Fura-2, a ratiometric calcium dye and imaged in real time with the 14-
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BIT CoolSNAP CCD camera). All calcium imaging was analyzed with PTI EasyRatioPro 
fluorescence imaging software. We conduced 3-4 independent experiments, resulting in 12-18 
cells analyzed per group (6), (27).  
Statistical analysis 
Data are presented as mean ± SD. Comparisons between more than two groups were made using 
one-way ANOVA followed by Tukey's post hoc test for multiple comparisons. For comparisons 
of differences between two groups the t-test was used.  A value of p < 0.05 was considered as 
being significantly different. Statistical Analyses of Muscle Contractility: Data points that were 
three standard deviations away from the mean were considered outliers and removed from the 
data set. Kolmogorov-Smirnov test was conducted to test for the normality assumption of the 
outcomes variables. All variables passed the normality test under the significance level of 0.05. 
A Mixed model approach was conducted to test for the treatment effect while accounting for the 
repeated measures on the same individual. Pairwise contrasts were estimated and tested for 
significance between different treatments. Due to the multiple comparisons of the contrasts, a 
more strict alpha level of 0.025 was used to establish the statistical significance. 
Results 
MLO-Y4 CM increased the contractile force of soleus muscle  
SOL muscle was treated with blank media as control and with 10% MLO-Y4 CM. The muscles 
were stimulated with two alternating frequencies of 20 Hz and 100 Hz.  MLO-Y4 CM increased 
the contractile force of SOL muscles at the 20 Hz frequency by ~25% (Fig. 1A) compared to 
blank media. 
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MLO-Y4 CM, Primary Osteocyte (PO) CM and WNT3a enhance myogenic differentiation 
of C2C12 cells, while Osteoblast CMs do not enhance myogenesis 
C2C12 cells were treated with MLO-Y4 CM, PO CM, and WNT3a, respectively. At day 3 of 
differentiation, control and treatment groups cells were stained with Anti-human Myosin Heavy 
Chain-CFS antibody which only stains maturing myocytes/myotubes not myoblasts and DAPI 
that stains only the nuclei (Fig. 1B). We also detected the specific fusion index (FI) of each 
experimental group. These data are summarized in Fig. 1C, showing that FI is significantly 
increased in the treatment groups compared with control. When C2C12 cells were treated with 
the 10% CM deriving from two different osteoblast cell lines, 2T3 (an established osteoblast cell 
line) and MC3T3-E1 (a preosteoblast cell line), respectively, there is no significant effects on the 
myogenic differentiation (Fig. 2A-B). 
Wnt3a mRNA is expressed in MLO-Y4 cell and 2T3 osteoblast cells and the expression 
increased after FFSS  
Wnt1, Wnt3a, Wnt4, Wnt5a and Wnt7a are involved in myogenesis (reviewed in (16)). To detect 
the gene expression of Wnt1, Wnt3a, Wnt4, Wnt5a and Wnt7a, we performed RT-qPCR in MLO-
Y4 and 2T3 cells. Our results show that Wnt3a is expressed in bone cells and is modulated by 
FFSS. These results are summarized and explained in detail in the legend of Fig. 3A-F. 
ELISA for WNT3a in PO CM and MLO-Y4 CM 
The only commercially available ELISA kit was used to detect WNT3a in MLO-Y4 CM and PO 
CM and the factor was detected in the 100-200 pg/mL range.  While this level might be 
considered low, we do see effects in vitro with WNT3a concentrations as low as 500 pg/mL. 
Furthermore, there are many technical reasons that might explain these results, including the fact 
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that it is technically challenging to isolate and purify WNT3A 
(http://web.stanford.edu/group/nusselab/cgi-bin/wnt/purification).  
Physiological concentrations of WNT3a and low concentrations of MLO-Y4 CM stimulate 
myogenesis of C2C12 cells  
Studies were performed with concentrations of WNT3a ranging from 0.1 to 10ng/mL as well as 
1% MLO-Y4 CM. A concentration as low as 0.5ng/mL to 10ng/mL WNT3a consistently 
enhanced the C2C12 cell differentiation (Fig. 4A and C).  In agreement with lower 
concentrations of WNT3a accelerating myogenesis, we also found that the myogenic 
differentiation of C2C12 cells was enhanced with as low as 1% MLO-Y4 CM. After 3 days of 
differentiation, a significant increase of the FI of MLO-Y4 CM-treated cells was found as 
compared with the control cells (Fig. 4B and D). 
MLO-Y4 CM, PO CM, and WNT3a induced translocation of β-Catenin to the nucleus of 
C2C12 cells  
To explore the possible roles of Wnt/β-catenin pathway in C2C12 cells, confocal microscopy 
was used to study the time course of the subcellular localization of β-catenin after C2C12 cells 
were treated with 10% MLO-Y4 CM, which demonstrated that peak translocation occurred at 60 
minutes (min) (Fig. 5A-B). Next, we tested the effects of C2C12 growth medium (GM), C2C12 
differentiation medium (DM), MLO-Y4 CM, PO CM, WNT3a and Lithium chloride as a 
positive control. The results demonstrated that β-catenin translocation to the nucleus was 
enhanced significantly by the different treatments when compared to GM. Furthermore, MLO-
Y4 CM, PO CM, WNT3a and Lithium chloride treatments were more potent than DM in 
inducing nuclear translocation of β-catenin (Fig. 5C-D). 
Treatment of C2C12 cells with MLO-Y4 siRNA-treated CM 
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To explore the roles of WNT3a from MLO-Y4 CM on C2C12 cells, MLO-Y4 osteocytes were 
transfected with Wnt3a siRNA. To detect siRNA transfection efficiency, MLO-Y4 osteocytes 
were transfected with 10 nM TYE 563 DS Transfection Control siRNA. Twenty four hours after 
transfection, images were taken, and the percentage of fluorescent positive cells was determined. 
The result revealed that the siRNA transfection efficiency of MLO-Y4 osteocytes was 80.02 ± 
7.18% (Fig. 6A). RT-qPCR was conducted to examine Wnt3a expression after knock down by 
Wnt3a siRNA.  The results indicated that the relative Wnt3a mRNA expression in the siRNA-
treated cells was 20.47 ± 4.72% of the negative control cells when normalized to expression of 
Gapdh, which was not altered by the negative control, vehicle control or siRNA treatments (Fig. 
6A), therefore ~80% of Wnt3a expression was knocked down. MLO-Y4 cells were treated with 
Wnt3a siRNA, and the CM (MLO-Y4 siRNA-treated CM) was collected. C2C12 cells were 
treated with MLO-Y4 siRNA-treated CM. At day 3 of differentiation, we measured the specific 
fusion index (FI) of each experimental group. These data are summarized in Fig. 6B-C, showing 
that in the cells treated with MLO-Y4 CM or the MLO-Y4 CM siRNA negative control, FI 
significantly increases, while in the cells treated with the MLO-Y4 siRNA-treated CM, FI did 
not increase and it is very similar to the negative control. (There was no difference between 
negative control and vehicle control). 
Treatment of C2C12 cells with Sclerostin inhibits the effects of MLO-Y4 CM and WNT3a 
on myogenic differentiation.   
Sclerostin is a Wnt signaling inhibitor (12). To study the effect of Sclerostin on C2C12 myoblast 
differentiation stimulation by MLO-Y4 CM and WNT3a, C2C12 myoblasts were pre-treated 
with 100ng/mL Sclerostin for 6 hours prior to the addition of MLO-Y4 CM and WNT3a. At day 
3 of differentiation, we measured the specific fusion index (FI) of each experimental group. FI 
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data of each group is summarized in Fig. 7A-B, showing that compared to negative control (a),  
FI of treatment group (b): C2C12 myoblasts were treated with 100ng/mL Sclerostin in DM for 6 
hours; treatment group (e): C2C12 myoblasts were treated with 100ng/mL Sclerostin in DM for 
6 hours, followed by 10% MLO-Y4 CM for 48 hours; treatment group (f): C2C12 myoblasts 
were treated with 100ng/mL Sclerostin in DM for 6 hours, followed by 10ng/mLWNT3a for 48 
hours was not significantly changed, and significantly reduced when compared to the positive 
controls (c and d), 10% MLO-Y4 CM and 10ng/mL WNT3a, respectively. The FI of treatment 
group (g): C2C12 myoblasts were treated with 100ng/mL Sclerostin in DM for 6 hours, followed 
by the combination of 10% MLO-Y4 CM + 10ng/mLWNT3a for 48 hours; increased 
significantly compared with negative control (DM), suggesting that only the MLO-Y4 CM + 
WNT3a together can overcome the inhibitory effect of Sclerostin. 
Modulation of Gene Expression by MLO-Y4 CM and WNT3a  
We employed the Mouse Signal Transduction PathwayFinder PCR Array to detect differences in 
expression of signaling molecules between control versus MLO-Y4 CM (10%) and WNT3a 
(10ng/mL) treated C2C12 cells at 24 hours after treatment. A major advantage of this technology 
is that monitors 10 different pathways simultaneously and is validated at the protein level.  We 
found a clear common shared gene regulation change in between 10% MLO-Y4 CM (Fig. 8A) 
and 10ng/mL WNT3a (Fig. 8B), which was the upregulation of the Wnt pathway detected by the 
overexpression of Wnt1 in the cells treated with CM and Wnt5a and Axin2 in the cells treated 
with WNT3a.  
We also employed RT-qPCR to detect the specific expression of myogenic differentiation 
markers (Mhc, MyoD and MyoG) and two Wnt/β-catenin downstream genes directly associated 
with C2C12 myogenesis (Fhl1 (29), Numb (30)). At day 3 of myotube differentiation, we found that 
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both 1% and 10% MLO-Y4 CM, as well as 0.5ng and10ng/mL WNT3a (except Numb in 1% 
MLO-Y4 CM) significantly increased the expression of these five specific genes (Fig. 8C-D).   
MLO-Y4 CM and WNT3a enhance caffeine induced SR calcium release  
Calcium homeostasis is very important in myoblast differentiation (31), and is a major surrogate 
of skeletal muscle function (27), (31). Avila et al (32) have demonstrated that WNT3a modulates 
intracellular Ca2+ in hippocampal neurons.  Furthermore, since our ex vivo muscle contractility 
experiments showed that the force produced by the lower frequency of stimulation was 
increased, to determine if SR calcium release was influenced by either MLO-Y4 CM or WNT3a, 
we employed an effective approach by testing the direct effects of caffeine’s ability to release 
calcium from the SR in Fura-2 loaded myotubes. In day 5 of myotube differentiation, caffeine 
responses were significantly larger in myotubes treated with 10% MLO-Y4 CM and 10ng/mL 
WNT3a as indicated by multiple and oscillatory peaks and a prolongation of the relaxation phase 
of the calcium transient response induced by caffeine (Fig. 9A).  
MLO-Y4 CM and WNT3a induced common gene overexpression profile of  
Ca2+ signaling/hypertrophy, Ca2+ homeostasis, mitochondrial biogenesis and oxidative 
stress genes  
Expression of important genes related to Ca2+ signaling/hypertrophy, Ca2+ homeostasis, 
mitochondrial biogenesis and oxidative stress in C2C12 cells at 60 hours of differentiation after 
treatments was detected by a focused custom-built RT-PCR gene array using the same 
technology that the PathwayFinder was used. In agreement with both the enhanced contractile 
force and SR calcium release by MLO-Y4 CM and WNT3a, the expression of these key 
regulatory pathways were significantly upregulated (Fig. 9B, and Table 3).  
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Discussion 
  Recent studies have shown that bone (osteoblasts and osteocytes) acts as an endocrine 
organ by the production and secretion of at least two circulating factors, FGF23 and osteocalcin 
(7). Osteocytes also secreted large amounts of PGE2, which we previously demonstrated to be a 
promoter of C2C12 myoblasts myogenesis (3) and proliferation (33). 
Our concept is that bone-muscle crosstalk enhances myogenic differentiation but may 
also have effects on muscle function. In this study, we showed that 10% MLOY4 CM and 10% 
BP CM enhanced C2C12 cell differentiation in vitro. In contrast, the differentiation was not 
significantly affected when C2C12 cells were treated with 10% 2T3 CM and 10% MC3T3-E1 
CM, respectively. In support of this we found that 10% MLOY4 CM increased the force 
production of SOL muscles stimulated ex vivo at lower frequencies of stimulation, suggesting 
that osteocytes release soluble factors that can either promote increased calcium release from the 
sarcoplasmic reticulum (SR) or enhance the sensitivity of the contractile machinery to calcium.  
Consistent with this, we showed that the caffeine-induced calcium release from the SR was 
significantly increased in C2C12 myotubes treated with MLO-Y4 CM and WNT3a. Another 
major motivation for the current study was the observation that WNT3a can activate MyoD and 
Myogenin (34), and these two genes are important myogenic regulatory factors.  WNT3a, that is 
found in the extracellular matrix of different cell types (35), is expressed in C2C12 cells and 2T3 
osteoblasts (36-38), and is detected at relatively high levels in serum of both humans (16.9 ± 
2.4ng/mL) and mice (0.225-3.74ng/mL) (39), suggesting a potential role of WNT3a in bone-
muscle crosstalk. In this study, we used RT-qRCR to detect Wnt3a expression after C2C12 
myoblasts were treated with MLO-Y4 CM, and found that Wnt3a expression was not altered 
(data not shown). We detected WNT3a in ~200 pg/mL range in MLO-Y4 CM and PO CM CMs 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
by using the only available commercial Elisa kit, and observed stimulation of myogenesis with 
as little as 500 pg/mL. While this difference seems large, when considering the log scale for the 
effects of drugs (i.e., dose-response relationship) perhaps this difference is not as profound as it 
appears to be. In addition, there are many technical reasons that might explain these results, 
including the fact that it is technically challenging to isolate and purify WNT3a (see 
http://web.stanford.edu/group/nusselab/cgi-bin/wnt/purification). Furthermore, it is possible that 
the continuous and chronic exposure of cells to pico-gram levels of WNT3a might lead to a host 
of cell biological effects. 
  To determine Wnt3a expression in MLO-Y4 and 2T3 cells, we investigated it at different 
time points and under static and FFSS conditions; and found that Wnt3a expression was 
modulated by FFSS. This finding is consistent with the results of Santos and colleagues who 
reported that MLO-Y4 cells subjected to Pulsating Fluid Flow (PFF) showed increased 
expression of Wnt3a.  Jia and colleagues found similar results in osteoblast cells, stimulated with 
PFF (40, 41).  These results might suggest that with increased levels of activity, bone-secreted 
WNT3a could increase, leading to signaling to muscle cells that modulate muscle function.  
       When C2C12 cells were treated with either 10% MLO-Y4 CM or PO CM, and 10ng/mL 
WNT3a, there was an enhancement of β-catenin translocation into the nucleus, providing 
evidence that the Wnt/β-catenin pathway is activated by CM and also by WNT3a. In contrast, 
when C2C12 cells were treated with either 10% 2T3 CM or 10% MC3T3-E1 CM (osteoblasts 
CMs), we did not observe any enhancement of myogenic differentiation, suggesting that factors 
secreted in the osteoblast CM are either different in nature or in concentration. This concept is 
further supported by the data from osteocytes showing that even 1% CM can enhance myogenic 
differentiation (Fig. 4B and 4D). 
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          To directly test the involvement of WNT3a as a mediator of the effects of CM, we treated 
MLO-Y4 cell with Wnt3a siRNA and collected the CM (MLO-Y4 siRNA-treated CM) (Fig. 6). 
When C2C12 cells were treated with 10% MLO-Y4 siRNA-treated CM, there was no significant 
change of C2C12 cell differentiation. This indicated that WNT3a is a key factor in MLO-Y4 CM 
responsible for the enhancement effect of C2C12 cell differentiation. 
     Next, to further explore if Wnt/β-catenin pathway was involved in the effect of MLO-Y4 
CM and WNT3a on C2C12 cell differentiation enhancement, we pre-treated C2C12 cells with 
Sclerostin which is a negative regulator of Wnt/β-catenin signaling pathway. Sclerostin inhibited 
the capacity of 10% MLO-Y4 CM and 10ng/mL WNT3a to enhance C2C12 cell differentiation, 
respectively, but failed to inhibit myogenic differentiation acceleration when CM and WNT3a 
were combined in the same treatment. These results support that Wnt/β-catenin signaling 
pathway is involved in MLO-Y4 CM and WNT3a enhancement of C2C12 cell differentiation. 
The reason that the combined treatment with MLO-Y4 CM and WNT3a together enhanced 
C2C12 cell differentiation may be because factors in MLO-Y4 CM (such as WNT3a, WNT1, et 
al) and WNT3a together reached a certain threshold that they competed with Sclerostin to bind 
to Lrp5 and Lrp6, then decrease the inhibition of Sclerostin on the Wnt/β-catenin signaling 
pathway. Furthermore, other factors in CM such as PGE2 could be contributing to the combined 
effects of CM and WNT3a. 
  To search for molecular insights into these effects of CM and WNT3a, we used the 
Mouse Signal Transduction PathwayFinder PCR Array and found that in 10% MLO-Y4 CM 
treatment, the expression of two protein coding genes Tnf and Wnt1 were significantly increased 
(Fig. 8A). Tnf  has been found to exert many of its effects on skeletal muscle through NFκB 
signaling (42). It has been reported that mechanical stimulation of  myoblasts leads to release of 
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TNF, which is necessary for myogenic differentiation (43). TNF is known to be one of the key 
regulators of skeletal muscle cell responses to injury. Whereas physiological levels of Tnf are 
transiently upregulated during myoblast regenerative responses to injury and stimulate 
differentiation, sustained high levels of TNF are associated with chronic inflammatory diseases 
and especially with muscle pathology associated with impairment of differentiation and muscle 
wasting. Wnt1 is directly involved in myogenesis (44). Based on this, we propose that MLO-Y4 
CM myogenic effect may be predominantly due to Tnf and Wnt1 activation. Since our data also 
show that WNT1 can enhance myogenesis (Supplemental Fig. 1A-C), the Wnt1 induced by 
MLOY4 CM might contribute to autocrine stimulation of the Wnt/β-catenin signaling pathway. 
An important question raised by our experiments with CMs and WNT3a was whether other Wnts 
might exert similar effects. We tested this possibility by treating C2C12 myoblasts with WNT1 
ranging from 0.5 to 100ng/mL. Interestingly, we found that the lower concentrations of WNT1 
did not increase differentiation, but 10ng/mL, 50ng/mL and 100ng/mL of WNT1 significantly 
enhanced myogenic differentiation in C2C12 cells, although even at these higher concentrations 
WNT1 was less potent than WNT3a. 
  When C2C12 cells were treated with 10ng/mL WNT3a, the expression of two genes 
(Axin2, Wnt5a) increased significantly (Fig. 8B). Axin2 associates directly with β-catenin, GSK-
3β and APC (adenomatous polyposis coli) and is induced by active Wnt signaling and acts in a 
negative feedback loop (16).  Thus, upregulation of this gene indicates activation of the Wnt/β-
catenin pathway. Wnt5a is involved in modulation of the non-canonical Wnt pathway, which 
regulates calcium inside cells (45). Therefore, providing strong evidence that WNT3a is acting via 
Wnt/β-catenin pathway and mobilizing intracellular calcium. 
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  In order to further confirm the enhancement of myogenic differentiation by both CM and 
WNT3a, we monitored with RT-qPCR the expression of two muscle regulatory factors (MRFs, 
MyoD and Myogenin) and one marker of terminal differentiation (Mhc) (Fig. 8C-D). Our results 
showed upregulation of these genes. To further dissect the mechanisms underlying these effects, 
we also measured the expression of two Wnt/β-catenin pathway downstream genes (Fhl1, 
Numb), which were both upregulated. Fhl1 was recently shown to be a downstream gene of the 
Wnt signaling pathway that promotes differentiation of C2C12 cells (29), and it has been reported 
that the expression of Numb was increased during C2C12 cell differentiation and that treatment 
with WNT3a increased both Numb gene and protein expressions (30). 
  Therefore, although not exactly the same genes, CM and WNT3a seem to be activating 
the Wnt/β-catenin pathway and upregulation MRFs. In addition, striking similarities of 
overlapping gene regulation by MLO-Y4 CM and WNT3a were revealed by our custom-built 
muscle specific RT-PCR gene array as summarized in Fig. 9B. Our muscle specific –RT PCR 
gene array results allowed us to demonstrate that both CM and WNT3a upregulated genes 
associated to pathways linked to Ca2+ signaling/hypertrophy, Ca2+ homeostasis, mitochondrial 
biogenesis and oxidative stress (Table 3). In support of our observations of enhanced force 
generation by SOL muscles induced by MLOY4 CM and increased myogenic differentiation and 
enhanced calcium released induced by both CM and WNT3a, we found overexpression of 
specific genes associated with SR calcium release (IP3Rs (46-48) and Fkbp1a (49, 50)), SR calcium 
uptake (SERCAs (51)), and store-operated calcium entry/myoblast differentiation (Stim 2) (52). 
These studies also revealed that three key Ca2+signaling genes (CamkII  (53, 54), Nfatc3 (52) and Srf  
(55)) critical for myotube homeostasis and cellular hypertrophy were also upregulated  as well as 
two genes associated with mitochondrial biogenesis and REDOX regulation  (PGC1α (56) and 
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SOD1 (57, 58)). Our results are also in agreement with previous reports that suggested the 
maintenance of normal intracellular Ca2+ concentration is vital to myocyte gene expression and 
differentiation (31).  It is also intriguing that Avila et al (32)  has reported that WNT3a modulates 
intracellular Ca2+ in hippocampal neurons, in fact, in a manner similar to that we have observed 
in muscle cells, suggesting that this might be a common mechanism in excitatory cells. We 
believe that the modulation in intracellular Ca2+ might work as the biophysical linker between the 
molecular-genetic adaptations and the changes (phenotypes) induced by WNT3a in muscle cells.   
           A recurring question in this emerging field of bone-muscle crosstalk is how secreted 
factors from bone and muscle can reach each other. Experiments performed by Fritton and 
colleagues (59) show that mouse tail vein injection of small dyes and molecules up to 70 kDa can 
permeate the osteocyte-lacunar-canalicular network in just a few minutes, which is bigger than 
the size of both WNT3a and WNT1(~40kDa), and in fact the majority of WNTs.  This 
demonstrates that the canalicular fluid has ready access to the circulation and suggests that 
factors secreted by osteocytes could enter the blood and have effects on distant target cells, 
including muscle. Furthermore, osteocytes are known to be the main producers of FGF23, which 
is readily detected in the serum, supporting an endocrine role for the osteocyte (reviewed in (7)). 
Another potential mechanism for the transport of factors between tissues is through 
microvesicles or extracellular vesicles (EVs), cell-derived membrane vesicles secreted by all cell 
types. The release of EVs is now recognized as an important modulator of crosstalk between 
many cells types, and in disease states (60). Recently, McBride et al (61) demonstrated that bone 
marrow mesenchymal stem cell derived exosomes transport WNT3a and enhance dermal 
fibroblast proliferation and angiogenesis in vitro.  
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Conclusions 
Obviously, a limitation of the current study is that we are not studying bone-muscle crosstalk in 
vivo, since this was beyond the scope of the current work. Importantly, the cell models and the ex 
vivo work did support the concept of bone to muscle signaling. In conclusion, our data showed 
that MLO-Y4 cells and primary osteocytes produce WNT3a. Bone-secreted factors contained in 
CM and WNT3a enhanced C2C12 cell differentiation through mechanisms associated with 
stimulation of the Wnt/β-catenin pathway and muscle regulatory factors. Osteocyte CM also 
increased the contractile function of ex vivo soleus muscles, which might be explained by the 
increased SR calcium release and the concurrent modulation of intracellular Ca2+ 
signaling/homeostasis. Furthermore, this modulation of Ca2+ signaling, might serve another 
purpose, by linking the effects of WNT3a through the activation of Wnt/β-catenin pathway, 
leading to specific phenotypic changes.  From our in vitro and ex vivo data, WNT3a could be one 
of the bone cell secreted factor(s) that promote differentiation of C2C12 myoblast. Our results 
support a concept that muscle and bone are not only communicating via mechanical interaction, 
but also that bone can secrete factor(s) that can act in a paracrine or endocrine fashion to support 
muscle differentiation and function. 
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Figure Legends 
Fig. 1. Osteocyte CM and WNT3a modulate the function of skeletal muscle. (A) MLO-Y4 
CM increased the contractile force of ex vivo intact SOL muscles. Original record shows the 
increase in 20 Hz force produced by 10% MLO-Y4 CM, on average the force increased by 25% 
(5 mice, 10 muscles, p < 0.05).  (B) MLO-Y4 CM, Primary Osteocyte (PO) CM, and WNT3a 
enhance myogenic differentiation.  Representative Fluorescence images of DAPI-stained nuclei 
(blue) and myosin heavy chain antibody (MHC, green) stained myocytes/myotubes of C2C12 
myoblasts after 3 days in 100% DM media (control), 10% PO CM, 10% MLO-Y4 CM and 
10ng/mL WNT3a. (C) Summary data for FI of control, PO CM, MLO-Y4 CM and WNT3a 
treatment. The treatment of 10% PO CM, 10% MLO-Y4 CM and10ng/mL WNT3a promoted 
myogenic differentiation compared to the control (n= 3-5, compared to control, 10% PO CM, p = 
0.001; 10% MLO-Y4 CM, p = 0.004; 10ng/mL WNT3a, p < 0.001). Calibration bar =100 µm. 
Fig. 2. Osteoblast CM does not increase myogenic differentiation. (A) Representative 
Fluorescence images of C2C12 myoblasts after 3 days in DM media (control), 10% 2T3 CM, 
and 10% MC3T3-E1 CM. (B) Summary data for FI of control, 2T3 CM and MC3T3-E1 CM 
treatment. The treatment of 10% 2T3 CM and 10% MC3T3-E1 CM had no significant effect on 
myogenic differentiation compared to the control (n= 3-5, compared to control, 10% 2T3 CM, p 
= 0.670; 10% MC3T3-E1 CM, p =1.000). Calibration bar =100 µm. 
Fig. 3. Expression of Wnt3a and other Wnt genes in MLO-Y4 cells and 2T3 cells. Summary 
data of RT-qRCR results at 24 and 48 hours of culture and 2 hours and 24 hours after FFSS in 
MLO-Y4 and 2T3 cells (A-F). (A) Wnt3a, Wnt1 and Wnt4 gene expression was detected in 
MLO-Y4 cells cultured for 24 and 48 hours while the expression of Wnt5a and Wnt7a was 
undetectable. At 48 hours, compared to 24 hours, the expression of Wnt3a increased significantly 
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by 1.995 fold, while the expression of Wnt1 and Wnt4 was not changed.  (B) In MLO-Y4 cells 
after FFSS treatment, compared to control, the expression of Wnt3a and Wnt1 increased 
significantly by 1.95 and 2 fold, respectively.  (C) No significant difference in expression of 
Wnt3a, Wnt1 and Wnt4 was detected at 24 hours after FFSS treatment, compared to control.  (D) 
In 2T3 cells, at 48 hours, compared to 24 hours, the expression of Wnt3a, Wnt1 and Wnt4 
increased significantly by 2.01, 1.99 and 4.02 fold, respectively. (E) In 2T3 cells after FFSS 
treatment, compared to control, the expression of WNT3a and Wnt1 increased significantly by 
2.02 and 7.98 fold, respectively, and expression of Wnt4 decreased by 50% (p = 0.004). (F), 
Compared to control, 24 after FFSS, the expression of Wnt3a increased by 11.9 fold and Wnt1 
and Wnt4 decreased by 50.1% (p = 0.001) and 50.7% (p = 0.001), respectively (n=3).  
Fig. 4. Lower concentrations, more physiological levels of WNT3a and 1% MLO-Y4 CM 
enhance C2C12 myoblast differentiation. Fluorescence images of DAPI-stained nuclei (blue) 
and myosin heavy chain antibody (MHC, green) stained myocytes/myotubes of C2C12 cells at 
differentiation day 3 after WNT3a treatment (A) and 1% MLO-Y4 CM (B). (C) Summary data 
for FI for treatments ranging from 0.1ng/mL to 10ng/mL WNT3a. FI increased significantly for 
concentration ranging from 0.5 to 10ng/mL WNT3a compared to control (n=3-5; compared to 
control, 0.5ng/mL WNT3a, p = 0.028; 1ng/mL WNT3a, p = 0.016; 2.5ng/mL WNT3a, p = 0.004; 
5ng/mL WNT3a, p = 0.001; 10ng/mL WNT3a, p < 0.001). (D) Summary data for 1% MLO-Y4 
CM-treated C2C12 cells at differentiation day3. FI increased significantly 1% MLO-Y4 CM 
compared to control (n=3-5, p = 0.014). Calibration bar =100 µm. 
Fig. 5. MLO-Y4 CM, PO CM, and WNT3a induced nuclear translocation of β-catenin in 
C2C12 myoblasts. (A) Immunostaining for β-catenin of C2C12 myoblasts at 30 minutes, 60 
minutes and 90 minutes after treatment  with 10% MLO-Y4 CM. (B) Quantification of the 
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nuclear β-catenin staining showed that the maximum induction of nuclear translocation of β-
catenin in C2C12 myoblasts occurred at 60 minutes (n=3, 5-10 cells per experiment, p < 0.001).  
(C) Confocal images of immunostaining for β-catenin of C2C12 cells cultured in GM, DM, 
treated 60 minutes in DM with 10% PO CM, 10% MLO-Y4 CM, 10ng/mL WNT3a and Lithium 
chloride was used as positive control. (D) Summary data show that compared to GM, DM 
promoted significantly higher nuclear translocation of β-catenin (n=3, 5-10 cells per experiment, 
p = 0.023) and compared to DM, PO CM, MLO-Y4 CM, WNT3a and LiCl induced significantly 
higher nuclear translocation of β-catenin (compared to DM, PO CM,  p < 0.001; MLO-Y4 CM,  
p = 0.003; WNT3a,  p < 0.001; LiCl, p < 0.001). 
Fig. 6. Wnt3a knockdown in MLO-Y4 cells impairs CM capacity to enhance myogenic 
differentiation. MLO-Y4 cells were transfected with Wnt3a siRNA. (A) Twenty hours after 
transfection, the transfection efficiency equaled 80.02 ± 7.18%, leading Wnt3a expression 
decreased to 20.47 ± 4.72% compared to negative control (n=3). (B) Fluorescence images of 
DAPI- and MHC stained C2C12 cells at differentiation day 3 after treatment of MLO-Y4 
siRNA-treated CM. (C) Summary data for FI for treatments ranging from DM control (a), 10% 
MLO-Y4 siRNA-treated CM (b), 10% CM from MLO-Y4 cells treated with negative control 
siRNA (c) and 10% MLO-Y4 CM as positive control (d). FI significantly increased in 10% CM 
from MLO-Y4 cells treated with negative control siRNA  and positive control compared to DM 
control, while no significant difference  was found in 10% MLO-Y4 siRNA-treated CM 
treatment (n=3; compared to control, b, p = 0.318; c, p < 0.001; d, p < 0.001). Calibration bar 
=100 µm. 
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Fig. 7. Sclerostin inhibits the effects of MLO-Y4 CM and WNT3a on myogenic 
differentiation. (A) Fluorescence images of DAPI and MHC stained C2C12 cells at 
differentiation day 3. (B) Summary data for FI for treatment groups: (a) DM without Sclerostin 
treatment as a negative control, (b) DM with 100ng/mL Sclerostin for 6 hours, (c) DM with 10% 
MLO-Y4 CM for 48 hours as one of our positive controls, (d) DM with 10ng/mL WNT3a for 48 
hours as our second positive control, (e) DM with 100ng/mL Sclerostin for 6 hours, followed by 
10% MLO-Y4 CM for 48 hours, (f) DM with 100ng/mL Sclerostin for 6 hours, followed by 
10ng/mLWNT3a for 48 hours, and (g) DM with 100ng/mL Sclerostin for 6 hours, followed by 
the combination of 10% MLO-Y4 CM + 10ng/mLWNT3a for 48 hours. # No significant 
difference of FI was found for groups (b), (e) and (f), compared to negative control (a), 
respectively. (n=3-6; compared to negative control, b, p = 0.925; e, p = 0.971; f: p =1.000). * FI 
increased significantly for group (g) and positive controls (c and d), compared to negative 
control. (n=3-6; compared to negative control, g, p = 0.030; c, p = 0.007; d, p < 0.001). 
Calibration bar =100 µm. 
Fig. 8. RT-PCR Gene Array and RT-qPCR detection of gene alterations in C2C12 cells 
after MLO-Y4 CM and WNT3a treatment. Summary data from 3 independent experiments 
for the Mouse Signal Transduction Pathway Finder PCR Array (A) In 10% MLO-Y4 CM, the 
expression of Tnf and Wnt1 were significantly increased (p = 0.031; p = 0.022, respectively). (B) 
When cells treated with 10ng/mL WNT3a, the expression of Axin2 and Wnt5a increased 
significantly (p < 0.001; p = 0.011, respectively). Summary data of RT-qRCR detection of gene 
expression changes for Mhc, MyoD, MyoG and Fhl1, Numb at differentiation day3 after 1%, 
10% MLO-Y4 CM (C) and 0.5ng/mL and 10ng/mL WNT3a treatment (D). The results 
demonstrated that both 1% and 10% MLO-Y4 CM, as well as 0.5ng and10ng/mL WNT3a 
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(except Numb in 1% MLO-Y4 CM, p = 0.084) significantly increased the expression of these 
five specific genes as compared to control (n=3, 2 replicates). Mhc, MyoD, MyoG and Fhl1 
increased significantly after 1% MLO-Y4 CM treatment (p = 0.002; p = 0.003; p = 0.004; p < 
0.043, respectively). Mhc, MyoD, MyoG, Fhl1 and Numb increased significantly after 10% 
MLO-Y4 CM treatment (p = 0.001; p < 0.001; p = 0.006, p = 0.002; p < 0.001, respectively). 
After 0.5ng/mL WNT3a treatment, Mhc, MyoD, MyoG, Fhl1 and Numb increased significantly 
(p = 0.004; p = 0.002; p = 0.001; p = 0.001; p < 0.001, respectively). After 10ng/mL WNT3a 
treatment, Mhc, MyoD, MyoG, Fhl1 and Numb increased significantly (p = 0.006; p = 0.001, p < 
0.001; p < 0.001, p < 0.001, respectively). 
Fig. 9. MLO-Y4 CM and WNT3a enhance Ca2+ release from the SR and modulate 
expression of key Ca2+ signaling/homeostasis genes. (A) Representative Ca2+ transient of 
C2C12 myotubes loaded with Fura-2/AM exposed to 20mM caffeine (arrows). MLO-Y4 CM 
and WNT3a treatment increased caffeine induced Ca2+ release in C2C12 myotubes. In 10% 
MLO-Y4 CM and 10ng/mL WNT3a-treated C2C12 myotubes, multiple oscillatory Ca2+ peaks in 
response to caffeine were observed and the relaxation phase of the transient was significantly 
longer (p < 0.05). (B) Increased expression of key genes related to Ca2+ signaling/hypertrophy, 
Ca2+ homeostasis, mitochondrial biogenesis and oxidative stress in C2C12 cells at 60 hours of 
differentiation after treatments was detected by a focused muscle custom-built RT-PCR gene 
array. Two PCR arrays provided similar results. 
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Table1. RT-qPCR primers used in this study 
Primer Primer sequence (5′ to 3′) 
GAPDHF TGCGATGGGTGTGAACCACGAGAA 
GAPDHR GAGCCCTTCCACAATGCCAAAGTT 
NumbF AACCAGCCTTTGTCCCTACC 
NumbR GGCGACTGATGTGGATGAG 
Fhl1F TTCTGGATCCCATCCTGTGTGAG 
Fhl1R ACACGGTACCTGGTTCCAATGCC 
MYHCF CAAGTCATCGGTGTTTGTGG 
MYHCR TGTCGTACTTGGGCGGGTTC 
MyoDF CCCCGGCGGCAGAATGGCTACG 
MyoDR GGTCTGGGTTCCCTGTTCTGTGT 
MyoGF TGAGCATTGTCCAGGCCAG 
MyoGR GCTTCTCCCTCAGTGTGGCT 
Wnt1F ATGAACCTTCACAACAACGAG 
Wnt1R GGTTGCTGCCTCGGTTG 
Wnt3aF TAGATGGGTGCGACCTGTTG 
Wnt3aR GAACCCTGCTCCCGTGTTAG 
Wnt4F CGAGGAGTGCCAATACCAGT 
Wnt4R GCCACACCTGCTGAAGAGAT 
Wnt5aF GGCGAGCTGTCTACCTGTGG 
Wnt5aR GGCGAACGGGTGACCATAGT 
Wnt7aF CGACTGTGGCTGCGACAAG 
Wnt7aR CTTCATGTTCTCCTCCAGGATCTTC 
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Table 2. Pathways and genes in Mouse Signal Transduction PathwayFinder PCR Array 
Signaling Pathways Genes 
TGFß Pathway Atf4, Cdkn1b (p27Kip1), Emp1, Gadd45b, Herpud1, Ifrd1, Myc, 
Tnfsf10 
WNT Pathway Axin2, Ccnd1, Ccnd2, Dab2, Fosl1 (Fra-1), Mmp7 (Matrilysin), Myc, 
Ppard, Wisp1 
NFκB Pathway Bcl2a1a (Bfl-1/A1), Bcl2l1 (Bcl-x), Birc3 (c-IAP1), Ccl5 (Rantes), 
Csf1 (Mcsf), Icam1, Ifng, Stat1, Tnf. 
JAK/STAT Pathway 
JAK1, 2 / STAT1 
STAT3 
STAT5 
JAK1, 3 / STAT6 
 
 
Irf1 
Bcl2l1 (Bcl-x), Ccnd1, Cebpd, Lrg1, Mcl1, Socs3 
Bcl2l1 (Bcl-x), Ccnd1, Socs3 
Fcer2a, Gata3 
p53 Pathway Bax, Bbc3, Btg2, Cdkn1a (p21Cip1/Waf1), Egfr, Fas (Tnfrsf6), 
Gadd45a, Pcna, Rb1 
Notch Pathway Hes1, Hes5, Hey1, Hey2, Heyl, Id1, Jag1, Lfng, Notch1 
Hedgehog Pathway Bcl2, Bmp2, Bmp4, Ptch1, Wnt1, Wnt2b, Wnt3a, Wnt5a, Wnt6 
PPAR Pathway Acsl3, Acsl4, Acsl5, Cpt2, Fabp1, Olr1, Slc27a4, Sorbs1 
Oxidative Stress Fth1, Gclc, Gclm, Gsr, Hmox1, Nqo1, Sqstm1, Txn1, Txnrd1 
Hypoxia Adm, Arnt, Car9, Epo, Hmox1, Ldha, Serpine1 (PAI-1), Slc2a1, Vegfa 
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Table 3. Pathways and genes in focused custom-built RT-PCR dene array 
 
Signaling Pathways Genes 
Ca2+ signaling/ cellular hypertrophy  Nfatc3 (52), CamkII  (53, 54), Srf  (55) 
Ca2+ homeostasis IP3-R1, IP3-R3 (46-48), Fkbp1a (49, 50), SERCA1a, 
SERCA2a (51), Stim 2 (52) 
Mitochondrial biogenesis PGC1α (56) 
Oxidative stress/Redox SOD1 (57, 58) 
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